Overview

Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Status:
Not yet recruiting

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

The trial aimed to compare cadonilimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in high-risk locoregionally-advanced nasopharyngeal carcinoma (LANPC).

Phase:

Phase 3

Details

Lead Sponsor:

Sun Yat-sen University

Collaborator:

Akeso Pharmaceuticals, Inc.

Treatments:

Antibodies, Bispecific
Cisplatin
Gemcitabine